Behcet syndrome

Behcet syndrome is a recurrent multiorgan inflammatory disorder and a systemic vasculitis that predominantly affects veins. This Primer reviews the epidemiology, pathophysiology, diagnosis and treatment of Behcet syndrome and describes its effect on patient quality of life and the future outlook for the field. Behcet syndrome is a systemic vasculitis with an unknown aetiology affecting the small and large vessels of the venous and arterial systems. The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn's disease suggest that multiple pathological pathways are involved in Behcet syndrome. These disease features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 as a genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bona fide disease, especially in non-endemic regions, suggests that other factors must also be operative in Behcet syndrome. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease, eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behcet syndrome, including those with eye disease, continue to improve. New treatment options and a better understanding of the underlying pathogenesis for various manifestations of this condition are required to further improve the management of the disease, which will improve patient quality of life.

Automated summary

Behcet syndrome is a systemic vasculitis that affects veins and arteries, with unknown etiology and multiple pathological pathways involved. While genetic factors like HLA-B*51 play a role in disease development, the low prevalence of HLA-B*51 in many patients suggests the presence of other influencing factors in Behcet syndrome.